Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 647 across all filing types
Latest filing 2025-10-15 Director's Dealing
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등거래계획보고서
Director's Dealing Classification · 95% confidence The document is titled '임원ㆍ주요주주특정증권등거래계획보고서' which translates to 'Report on Trading Plans of Executives and Major Shareholders' specific securities. It contains detailed information about the ownership and planned transactions of specific securities by a major shareholder or executive, including quantities, transaction dates, prices, and legal confirmations. There is no indication of financial statements, earnings data, or management discussion. The document is a regulatory disclosure about insider or major shareholder planned transactions in securities, which aligns with the category of Director's Dealing (DIRS). The document length is about 5,244 characters, which is sufficient for a detailed report rather than a brief announcement. Therefore, the classification is DIRS with high confidence.
2025-10-15 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a stock collateral contract involving a change in the largest shareholder. It includes specifics about the collateral provider, debt amounts, contract dates, and related parties. There is no indication of financial statements, audit opinions, or management discussions typical of annual or interim reports. The content focuses on financing arrangements and collateral details, which aligns with capital or financing updates. The document length is about 5,193 characters, which is sufficient for a substantive announcement rather than a brief notice. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2025-10-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서(일반)' which translates to 'Report on Large Shareholding Status (General)'. It contains detailed information about shareholdings, changes in share ownership, related contracts, and voting rights percentages. The document references specific dates and legal provisions related to capital markets and financial investment laws. It is a comprehensive report on significant share ownership and related contractual arrangements, not an announcement or a brief summary. This matches the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels. The document is lengthy (over 13,000 characters) and contains substantive data, so it is not a mere announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2025-10-15 Korean
소송등의제기ㆍ신청(일정금액이상의청구)
Legal Proceedings Report Classification · 100% confidence The document is a notification regarding a legal proceeding involving a payment order application with a significant claim amount. It details the parties involved, claim amount, court jurisdiction, and the company's planned response. The content focuses on legal matters and updates about a lawsuit or legal claim rather than financial results, management changes, or shareholder information. The document length is short (1200 characters) and it is clearly about a legal proceeding update. Therefore, it fits the category of Legal Proceedings Report (LTR).
2025-10-14 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a stock collateral provision contract involving a change in the largest shareholder. It includes specific financial figures related to debt amounts, collateral stock numbers, contract dates, and details about the debtor and creditor parties. The content focuses on financing arrangements and collateral agreements rather than financial results, management changes, or regulatory certifications. The document length is over 5,000 characters and contains substantive financial and contractual data related to capital structure and financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-10-13 Korean
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 95% confidence The document is titled '증권신고서(지분증권) 6.1 (주)젬백스앤카엘 정 정 신 고 (보고)' which translates to 'Securities Registration Statement (Equity Securities) 6.1 GemVax & Kael Co., Ltd. Amendment Report'. It includes detailed information about a rights offering (유상증자), including issuance schedules, subscription methods, allocation ratios, and regulatory references to the Financial Supervisory Service (금융감독원). The document is a corrected or amended securities registration statement, which is a regulatory filing related to capital raising and securities issuance. It is not an annual report, earnings release, or management report. It is not a short announcement but a detailed filing with substantive content about the securities offering. This type of document corresponds to a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes through a rights offering and issuance of new shares and warrants. Therefore, the correct classification is CAP with high confidence.
2025-10-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.